Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Prakash Sarvepalli

Internal Medicine Edmore, MI Medical Doctor

NPI 1669411310 CMS profile 120889

1021 E. Main Street, Edmore, MI 48829

Open in the dashboard

General payments

$7,974

420 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Prakash Sarvepalli of Edmore, MI is reported in the CMS Open Payments database as having received $7,974 across 420 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $968 52
2024 General $1,410 69
2023 General $829 45
2022 General $966 53
2021 General $863 51
2020 General $793 55
2019 General $2,145 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Prakash Sarvepalli
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Prakash Sarvepalli were reported at $968. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Prakash Sarvepalli Internal Medicine median Middle half National median
2019 $2,145 $159 $48–$570 $163
2020 $793 $119 $33–$402 $114
2021 $863 $135 $37–$521 $132
2022 $966 $141 $42–$496 $149
2023 $829 $149 $45–$519 $160
2024 $1,410 $154 $47–$537 $164
2025 $968 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,181 63 payments
  2. AbbVie, Inc. $762 48 payments
  3. Lilly USA, LLC $460 30 payments
  4. Otsuka America Pharmaceutical, Inc. $433 17 payments
  5. AstraZeneca Pharmaceuticals LP $395 20 payments
  6. Pfizer Inc. $365 26 payments
  7. Astellas Pharma US Inc $364 15 payments
  8. Janssen Pharmaceuticals, Inc $358 22 payments
  9. Amgen Inc. $345 19 payments
  10. Sanofi-Aventis U.S. LLC $274 13 payments
  11. Other $3,038 147 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,817 415 payments
  2. Education $149 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $699 32 payments
  2. RYBELSUS $439 27 payments
  3. VRAYLAR $353 21 payments
  4. REXULTI $309 16 payments
  5. Saxenda $261 17 payments
  6. FARXIGA $229 9 payments
  7. Repatha $225 13 payments
  8. MYRBETRIQ $221 12 payments
  9. XARELTO $219 14 payments
  10. ENTRESTO $204 11 payments
  11. Other $6,776 381 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 242 drugs

Part D claims

17,133

Median for Internal Medicine: 777

Drug cost

$1,170,850

Median for Internal Medicine: $73,373

Branded share of claims

23.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 382 $203,072
Trulicity Dulaglutide Brand 82 $114,024
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 95 $77,914
Xarelto Rivaroxaban Brand 118 $44,007
Ozempic Semaglutide Brand 25 $32,359
Jardiance Empagliflozin Brand 35 $32,351
Budesonide Generic 148 $30,902
Myrbetriq Mirabegron Brand 35 $30,332
Xifaxan Rifaximin Brand 18 $29,730
Januvia Sitagliptin Phosphate Brand 32 $19,623

The 10 drugs with the highest cost, of 242 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$133,114

Of which drugs: $379

Medicare patients

314

Average age 73

Services billed

5,420

166 women, 148 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 63%
Depression 49%
Arthritis 46%
Ischemic heart disease 41%
COPD 40%
Diabetes 37%
Chronic kidney disease 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 33 2,522 $262
Injection, methylprednisolone acetate, 80 mg J1040 Office 13 9 $54
Injection, ceftriaxone sodium, per 250 mg J0696 Office 24 156 $52
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 16 45 $0

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $143
  • Lundbeck LLC $75
$219 — —
VRAYLAR
  • AbbVie, Inc. $179
$179 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $125
$125 30 —
RYBELSUS
  • Novo Nordisk Inc $71
$71 — —
Ozempic
  • Novo Nordisk Inc $71
$71 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

420 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record